Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time to dive into all of the latest stock market news for Tuesday morning as we go over the biggest pre-market stock movers! We’ve got a reverse stock split, new ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Regis (NYSE: RGS ) stock leads our gainers on a partnership. DocuSign (NASDAQ: DOCU ) stock tops out losers on an earnings report. Clinical trials have several stocks moving today. Source: oneinchpunch...
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 3:30 p....
Abeona Therapeutics (NASDAQ:ABEO) has been granted additional 180-day by Nasdaq to regain compliance with the $1.00 minimum bid price requirement for continued listing. Common stock continues to trade on the Nasdaq Capital Market under the symbol "ABEO." Nasdaq will provide the company with w...
NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been granted an additional 180-day period from Nasdaq’s Listing Qualification Department, through...
Abeona Therapeutics Inc. (ABEO) Q1 2022 Earnings Conference Call May 17, 2022 8:30 am ET Company Participants Vishwas Seshadri - Chief Executive Officer Joseph Vazzano - Chief Financial Officer Brian Kevany - Chief Technical Officer, Head of Research Greg Gin - Vice President, Investor Relati...
Ultragenyx Pharmaceutical (NASDAQ:RARE) is acquiring global rights to Abeona Therapeutics' (NASDAQ:ABEO) AAV gene therapy ABO-102 (now UX111) to treat Sanfilippo syndrome type A (MPS IIIA). Sanfilippo syndrome is a rare, fatal genetic condition that causes brain degeneration, and ca...
ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy (ASGCT) today NOVATO, Calif. and NEW YORK and CLEVELAND, May 17, 2022 (GLOBE N...
Abeona Therapeutics press release (NASDAQ:ABEO): Q1 GAAP EPS of -$0.14 misses by $0.04. Revenue of $0.35M. Cash, cash equivalents, restricted cash and short-term investments totaled $37.2 million as of March 31, 2022. Shares +0.57% PM For further details see: Abeona Therapeutics GAAP EP...
Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023 Focus R&D resources on EB-101 pivotal phase 3 VIITAL™ topline data expected in 3Q 2022 NEW YORK and CLEVELAND, May 13, 2022 (GLOBE NEWSWIRE) -- Abeona ...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter ...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchas...